Anhui Bonomic Biomedical Co., Ltd.

Main research purpose: Use minodronic acid tablets (trade name: Bonoteo, specification: 1mg/tablet) produced by Aisuo Biotech Co., Ltd. as the reference preparation, and use minodronic acid provided by Anhui Bonomeco Biopharmaceutical Co., Ltd. The tablet (specification: 1 mg/tablet) is the test preparation. A randomized, open-label, single-dose, four-cycle, fully repeated crossover design was adopted to compare the effects of minodronic acid after subjects took the test preparation and the reference preparation in the fasting state. The absorption rate and extent were evaluated to evaluate the bioequivalence of the two preparations in Chinese healthy subjects under fasting state. Secondary research purpose: To evaluate the safety of the test preparation minodronic acid tablets (specification: 1mg/tablet) and the reference preparation minodronic acid tablets (trade name: Bonoteo, specification: 1mg/tablet) orally administered to Chinese healthy subjects sex.

Main research purpose: Use minodronic acid tablets (trade name: Bonoteo, specification: 1mg/tablet) produced by Aisuo Biotech Co., Ltd. as the reference preparation, and use minodronic acid provided by Anhui Bonomeco Biopharmaceutical Co., Ltd. The tablet (specification: 1 mg/tablet) is the test preparation. A randomized, open-label, single-dose, four-cycle, fully repeated crossover design was adopted to compare the effects of minodronic acid after subjects took the test preparation and the reference preparation in the fasting state. The absorption speed and extent, and the intra-individual variability of key pharmacokinetic parameters are examined to provide a basis for determining the sample size of the formal test and optimizing the test plan. Secondary research purpose: To observe the safety of the test preparation minodronic acid tablets (specification: 1mg/tablet) and the reference preparation minodronic acid tablets (trade name: Bonoteo, specification: 1mg/tablet) orally administered to Chinese healthy subjects sex.

Main research purpose: Using bisoprolol amlodipine tablets (trade name: Kangxinan®, specifications: bisoprolol fumarate 5mg and amlodipine besylate (calculated as amlodipine) 5mg) produced by licensed manufacturer Merck Kft, Egis Pharmaceuticals PLC as reference preparation, and bisoprolol amlodipine tablets (specifications: bisoprolol fumarate 5mg and amlodipine besylate (calculated as amlodipine) 5mg) provided by Anhui Bonomeco Biopharmaceutical Co., Ltd. as test preparation, a randomized, open, single-dose, two-period double crossover design was used to evaluate the bioequivalence of the two preparations in fasting and fed states in healthy Chinese subjects. Secondary study objective: To evaluate the safety of the oral test preparation bisoprolol amlodipine tablets (specifications: bisoprolol fumarate 5 mg and amlodipine besylate (calculated as amlodipine) 5 mg) and the reference preparation (trade name: Kangxinan®, specifications: bisoprolol fumarate 5 mg and amlodipine besylate (calculated as amlodipine) 5 mg) in healthy Chinese subjects.